ATE419375T1 - Amplifizierung von cyp24 und anwendung dafür - Google Patents

Amplifizierung von cyp24 und anwendung dafür

Info

Publication number
ATE419375T1
ATE419375T1 AT00916145T AT00916145T ATE419375T1 AT E419375 T1 ATE419375 T1 AT E419375T1 AT 00916145 T AT00916145 T AT 00916145T AT 00916145 T AT00916145 T AT 00916145T AT E419375 T1 ATE419375 T1 AT E419375T1
Authority
AT
Austria
Prior art keywords
cyp24
level
cancer
animal
biological sample
Prior art date
Application number
AT00916145T
Other languages
English (en)
Inventor
Donna Albertson
Daniel Pinkel
Colin Collins
Joe Gray
Bauke Ystra
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE419375T1 publication Critical patent/ATE419375T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00916145T 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür ATE419375T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/285,292 US7648826B1 (en) 1999-04-02 1999-04-02 Detecting CYP24 expression level as a marker for predisposition to cancer

Publications (1)

Publication Number Publication Date
ATE419375T1 true ATE419375T1 (de) 2009-01-15

Family

ID=23093617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916145T ATE419375T1 (de) 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür

Country Status (7)

Country Link
US (4) US7648826B1 (de)
EP (1) EP1255850B1 (de)
JP (1) JP4790127B2 (de)
AT (1) ATE419375T1 (de)
CA (1) CA2367291C (de)
DE (1) DE60041278D1 (de)
WO (1) WO2000060109A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
HUE029572T2 (en) 2006-02-03 2017-03-28 Opko Renal Llc Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
EP3542792B1 (de) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Kontrollierte freisetzung 25-hydroxyvitamin d
CN101878315A (zh) 2007-11-30 2010-11-03 基因特力株式会社 使用膀胱癌特异性甲基化标记基因的膀胱癌诊断试剂盒和芯片
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
US8614071B2 (en) * 2009-12-11 2013-12-24 Roche Molecular Systems, Inc. Preferential amplification of mRNA over DNA using chemically modified primers
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
US9135694B2 (en) 2012-12-04 2015-09-15 General Electric Company Systems and methods for using an immunostaining mask to selectively refine ISH analysis results
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN114681468A (zh) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
TW202214257A (zh) 2016-03-28 2022-04-16 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素d治療之方法
CN113267529B (zh) * 2021-05-12 2022-10-25 江西师范大学 一种温度型生物传感器及利用温度型生物传感器检测目标适体的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002539A1 (en) 1996-07-15 1998-01-22 The Regents Of The University Of California GENES FROM 20q13 AMPLICON AND THEIR USES
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US7427670B2 (en) * 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof

Also Published As

Publication number Publication date
US8685929B2 (en) 2014-04-01
JP4790127B2 (ja) 2011-10-12
EP1255850A4 (de) 2005-02-09
US20120322674A1 (en) 2012-12-20
US8173602B2 (en) 2012-05-08
US20100285023A1 (en) 2010-11-11
DE60041278D1 (de) 2009-02-12
US20140187441A1 (en) 2014-07-03
WO2000060109A1 (en) 2000-10-12
JP2002540798A (ja) 2002-12-03
EP1255850B1 (de) 2008-12-31
US7648826B1 (en) 2010-01-19
CA2367291A1 (en) 2000-10-12
EP1255850A1 (de) 2002-11-13
CA2367291C (en) 2012-05-15

Similar Documents

Publication Publication Date Title
ATE419375T1 (de) Amplifizierung von cyp24 und anwendung dafür
Chay et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
DE60238132D1 (de) Patientenklassifizierung
WO2005084109A3 (en) Cancer specific gene mh15
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
ATE406575T1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
WO2004000094A3 (en) Predictive markers in cancer therapy
Bock et al. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer
JIN et al. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters
Tellez et al. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2α and protease-activated receptor-1 expression during melanoma progression
ATE350662T1 (de) Markerproteine für prostatakrebs
Gochman et al. NF-κB activation by peroxynitrite through IκBα-dependent phosphorylation versus nitration in colon cancer cells
Deng et al. Inhibition of cancer cell migration with CuS@ mSiO2-PEG nanoparticles by repressing MMP-2/MMP-9 expression
Chaudary et al. Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2002077197A3 (en) Methods for diagnosing and monitoring malignancies by screening gene copy numbers
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
NZ332641A (en) method of detecting a lysosomal storage disorder by assaying the level of an enzyme, protein or peptide associated with the disease
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties